Aprea Therapeutics (NASDAQ:APRE) Given “Outperform” Rating at Wedbush

Wedbush reaffirmed their outperform rating on shares of Aprea Therapeutics (NASDAQ:APRE) in a research note published on Thursday morning,RTT News reports. The brokerage currently has a $11.00 target price on the stock.

Aprea Therapeutics Trading Down 2.6%

APRE opened at $1.75 on Thursday. Aprea Therapeutics has a 1-year low of $1.41 and a 1-year high of $5.01. The stock has a market capitalization of $9.69 million, a PE ratio of -0.74 and a beta of 1.22. The firm has a 50-day moving average price of $1.72 and a two-hundred day moving average price of $2.52.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.01). Aprea Therapeutics had a negative net margin of 1,095.02% and a negative return on equity of 68.39%. The company had revenue of $0.16 million for the quarter. On average, research analysts predict that Aprea Therapeutics will post -2.55 EPS for the current year.

Institutional Investors Weigh In On Aprea Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Stonepine Capital Management LLC increased its position in Aprea Therapeutics by 8.8% in the fourth quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock worth $491,000 after purchasing an additional 12,047 shares during the period. BNP Paribas Financial Markets bought a new stake in Aprea Therapeutics during the 4th quarter worth approximately $43,000. LPL Financial LLC bought a new stake in Aprea Therapeutics during the 4th quarter worth approximately $53,000. Finally, Landscape Capital Management L.L.C. acquired a new stake in Aprea Therapeutics during the 4th quarter worth approximately $116,000. 34.19% of the stock is owned by institutional investors and hedge funds.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.